![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Tompkins C, Cheng A, Dalal D et al. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J. Am. Coll. Cardiol.55(21), 2376–2382 (2010).
- Douketis JD, Berger PB, Dunn AS et al. The perioperative management of anti-thrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines (eighth edition). Chest133(6), 299S–339S (2008).
- Garcia DA, Regan S, Henault LE et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch. Intern. Med.168(1), 63–69 (2008).
- Michaud GF, Pelosi F Jr, Noble MD et al. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J. Am. Coll. Cardiol.35(7), 1915–1918 (2000).
- Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin. Electrophysiol.21, 1730–1734 (1998).
- Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients. Pacing Clin. Electrophysiol.26, 511–514 (2003).
- Giudici MC, Barold SS, Paul DL, Bontu P. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin. Electrophysiol.27, 358–360 (2004).
- Marquie C, De Geeter G, Klug D et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace8, 283–287 (2006).
- Cheng M, Hua W, Chen K et al. Perioperative anticoagulation for patients with mechanical heart valves undertaking pacemaker implantation. Europace11, 1183–1187 (2009).
- Wiegand UKH, LeJeune D, Boguschewski F et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery. Chest126(4), 1177–1186 (2004).
- Robinson M, Healey JD, Eikelboom J et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin. Electrophysiol.32, 378–382 (2009).
- Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am. Heart J.158(2), 252–256 (2009).
- Dreger HK, Grohmann A, Bondke H et al. Is antiarrhythmic device implantation safe under dual antiplatelet therapy? Pacing Clin. Electrophysiol.33, 394–399 (2010).
- Tolosana JM, Berne P, Mont L et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thromboembolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Euro. Heart J.30, 1880–1884 (2009).
- Cheng A, Nazarian S, Brinker JA et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm8(4), 536–540 (2011).
- Ghanbari H, Feldman D, Schmidt M et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin. Electrophysiol.33(4), 400–406 (2010).
- Grines CL, Bonow RO, Casey DE Jr et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J. Am. Coll. Cardiol.40, 734–739 (2007).
- Birnie D, Healey JS, Krahn A et al. Bridge or continue coumadin for device surgery: a randomized controlled trial rational and design. Curr. Opin. Cardiol.24, 82–87 (2009).